Prevalence of multimorbidity among the HIV-infected individuals receiving anti-viral therapy in Dehong Prefecture,Yunnan Province
[Objective]To explore the prevalence and influencing factors of multimorbidity among the HIV-infected individuals receiving anti-viral therapy(ART)in Dehong Prefecture of Yunnan Province,so as to provide a reference for the long-term follow-up management of HIV-infected patients and the comprehensive prevention and treatment of chronic diseases.[Methods]A cross-sectional study was conducted to investigate the multimorbidity burden among the HIV-infected adults receiving ART in Dehong Prefecture from January to July 2021 and a self-designed questionnaire was used to analyze relevant disease indicators.Multivariate logistic regression analysis was used to investigate the influencing factors of multimorbidity among the HIV-infected individuals.[Results]A total of 3 946 HIV-infected individuals receiving ART were enrolled in this study,of which 63.7%aged≤50 years,with a male to female ratio of 1.1∶1.Among the 3 946 cases,825 of them had≥2 comorbidities,with a co-prevalence rate of 20.9%(95%CI:19.6%‒22.2%),and the main comorbidities were dyslipidemia,diabetes,and hypertension.Multivariate logistic regression analysis showed that 40≤aged<50 years(a OR=1.86,95%CI:1.45‒2.40,P<0.001),50≤aged≤85 years(a OR=3.75,95%CI:2.93‒4.80,P<0.001),Dai nationality(a OR=1.21,95%CI:1.01‒1.47,P=0.043),BMI≥24.0 kg∙m-2(a OR=1.79,95%CI:1.49‒2.14,P<0.001),10.0≤with ART duration for<12.5 years(a OR=1.49,95%CI:1.05‒2.12,P=0.024),with ART duration for≥12.5 years(a OR=1.50,95%CI:1.05‒2.15,P=0.026),use of second-line HIV therapy(a OR=1.43,95%CI:1.19‒1.70,P<0.001)and other therapy options(a OR=3.16,95%CI:2.17‒4.61,P<0.001)were positively correlated with multimorbidity.[Conclusion]The prevalence of multimorbidity among the HIV-infected individuals receiving ART in Dehong Prefecture is high,which is associated with the advancing age and prolonged treatment time,particularly with a significant burden of dyslipidemia,diabetes,and hypertension.Comprehensive surveillance and targeted management of comorbidities,along with ART follow-up,need to be strengthened in the future.
human immunodeficiency virusanti-viral therapymultimorbiditycross-sectional studyinfluencing factor
万方数据
维普
